Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Other Accumulated Expenses: 2018-2024

Historic Other Accumulated Expenses for Tg Therapeutics (TGTX) over the last 7 years, with Dec 2024 value amounting to $4.6 million.

  • Tg Therapeutics' Other Accumulated Expenses fell 39.57% to $2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year decrease of 39.57%. This contributed to the annual value of $4.6 million for FY2024, which is 212.85% up from last year.
  • Latest data reveals that Tg Therapeutics reported Other Accumulated Expenses of $4.6 million as of FY2024, which was up 212.85% from $1.5 million recorded in FY2023.
  • In the past 5 years, Tg Therapeutics' Other Accumulated Expenses ranged from a high of $18.2 million in FY2020 and a low of $1.2 million during FY2022.
  • Over the past 3 years, Tg Therapeutics' median Other Accumulated Expenses value was $1.5 million (recorded in 2023), while the average stood at $2.4 million.
  • Per our database at Business Quant, Tg Therapeutics' Other Accumulated Expenses plummeted by 91.71% in 2021 and then soared by 212.85% in 2024.
  • Yearly analysis of 5 years shows Tg Therapeutics' Other Accumulated Expenses stood at $18.2 million in 2020, then crashed by 91.71% to $1.5 million in 2021, then dropped by 22.69% to $1.2 million in 2022, then increased by 26.52% to $1.5 million in 2023, then soared by 212.85% to $4.6 million in 2024.